Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 2, 2026 by admin

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

Conditions: Major Depressive Episode (MDE); Major Depressive Disorder (MDD); Depression

Interventions: Drug: TNX-102 SL; Drug: Placebo sublingual tablet

Sponsors: Tonix Pharmaceuticals, Inc.

Recruiting
CategoriesClinicalTrials.gov TagsAcademic research, Depression, Mood and emotional regulation, News Approved

Post navigation

Previous PostPrevious Exploring the Feasibility of Transcranial Ultrasound Stimulation in the Treatment of Schizophrenia
Next PostNext Comparing Outcomes of Theta Burst Stimulation in Depression Using Advanced PET Imaging
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.